Pharmacologic interventions for antidepressant-induced sexual dysfunction: a systematic review and network meta-analysis of trials using the Arizona sexual experience scale
| Autor: | Paul E. Croarkin, Jeffrey R. Strawn, Marissa J. Luft, Eric T. Dobson, Amir Levine |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry Sildenafil Psychological intervention Placebo medicine.disease law.invention Psychiatry and Mental health chemistry.chemical_compound Sexual dysfunction Erectile dysfunction chemistry Randomized controlled trial Strictly standardized mean difference law Meta-analysis Internal medicine medicine Neurology (clinical) medicine.symptom business |
| Zdroj: | CNS Spectrums. :1-10 |
| ISSN: | 2165-6509 1092-8529 |
| Popis: | Background Despite the prevalence of antidepressant-related sexual side effects, comparisons of treatments for these problematic side effects are lacking. Methods To address this, we performed a systematic review and Bayesian network meta-analysis to compare interventions for antidepressant-induced sexual dysfunction in adults. Using PubMed and clinicaltrials.gov, we identified published and unpublished prospective treatment trials from 1985 to September 2020 (primary outcome: the Arizona sexual experience scale [ASEX] score). The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework. Results We identified 57 citations (27 randomized controlled trials, 66 treatment arms, 27 open-label trials, and 3 crossover trials) that evaluated 33 interventions (3108 patients). In the systematic review, 44% (25/57) of trials reported successful interventions; this was more common in open-label (70%, 19/27) compared to placebo-controlled studies (22%, 6/27). In the meta-analysis of placebo-controlled studies that used the ASEX (N = 8), pycnogenol was superior to placebo (standardized mean difference: −1.8, 95% credible interval [CrI]: [−3.7 to 0.0]) and there was evidence that, at a 6% threshold, sildenafil improved sexual dysfunction (standardized mean difference: −1.2, 95% CrI [−2.5 to 0.1]). In the meta-analysis including single-arm studies (15 studies), treatment response was more common with sildenafil, tianeptine, maca, tiagabine, and mirtazapine compared to placebo, but these differences failed to reach statistical significance. Conclusions While heterogeneity across randomized controlled trials complicates identifying the single best intervention, multiple trials suggest that sildenafil ameliorates antidepressant-induced sexual dysfunction. More randomized controlled trials are needed to examine the putative efficacy of other interventions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|